119-hr3821

HR
✓ Complete Data

ADINA Act

Login to track bills
Introduced:
Jun 6, 2025
Policy Area:
Health

Bill Statistics

4
Actions
11
Cosponsors
0
Summaries
1
Subjects
1
Text Versions
Yes
Full Text

AI Summary

No AI Summary Available

Click the button above to generate an AI-powered summary of this bill using Claude.

The summary will analyze the bill's key provisions, impact, and implementation details.

Latest Action

Jun 6, 2025
Referred to the House Committee on Energy and Commerce.

Actions (4)

Referred to the House Committee on Energy and Commerce.
Type: IntroReferral | Source: House floor actions | Code: H11100
Jun 6, 2025
Sponsor introductory remarks on measure. (CR H2516)
Type: IntroReferral | Source: Library of Congress | Code: B00100
Jun 6, 2025
Introduced in House
Type: IntroReferral | Source: Library of Congress | Code: Intro-H
Jun 6, 2025
Introduced in House
Type: IntroReferral | Source: Library of Congress | Code: 1000
Jun 6, 2025

Subjects (1)

Health (Policy Area)

Cosponsors (7 of 11)

Showing latest 7 cosponsors

Text Versions (1)

Introduced in House

Jun 6, 2025

Full Bill Text

Length: 2,523 characters Version: Introduced in House Version Date: Jun 6, 2025 Last Updated: Nov 15, 2025 2:30 AM
[Congressional Bills 119th Congress]
[From the U.S. Government Publishing Office]
[H.R. 3821 Introduced in House

(IH) ]

<DOC>

119th CONGRESS
1st Session
H. R. 3821

To amend the Federal Food, Drug, and Cosmetic Act to require the label
of a drug intended for human use to identify each ingredient in such
drug that is, or is derived directly or indirectly from, a major food
allergen or a gluten-containing grain, and for other purposes.

_______________________________________________________________________

IN THE HOUSE OF REPRESENTATIVES

June 6, 2025

Ms. Morrison (for herself, Mr. Lawler, Ms. Matsui, Mr. Cline, Mr.
Fitzpatrick, and Mr. Bacon) introduced the following bill; which was
referred to the Committee on Energy and Commerce

_______________________________________________________________________

A BILL

To amend the Federal Food, Drug, and Cosmetic Act to require the label
of a drug intended for human use to identify each ingredient in such
drug that is, or is derived directly or indirectly from, a major food
allergen or a gluten-containing grain, and for other purposes.

Be it enacted by the Senate and House of Representatives of the
United States of America in Congress assembled,
SECTION 1.

This Act may be cited as the ``Allergen Disclosure In Non-food
Articles Act'' or the ``ADINA Act''.
SEC. 2.
ALLERGEN OR IS MADE FROM A GLUTEN-CONTAINING GRAIN.

(a) Misbranding.--
Section 502 of the Federal Food, Drug, and Cosmetic Act (21 U.
Cosmetic Act (21 U.S.C. 352) is amended by adding at the end the
following:
``

(hh) If it is a drug--
``

(1) that is intended for human use;
``

(2) that contains an ingredient that is, or is derived
directly or indirectly from--
``
(A) a major food allergen; or
``
(B) a gluten-containing grain (including wheat,
barley, rye, and their crossbred hybrids); and
``

(3) whose label fails--
``
(A) to state that the drug contains such an
ingredient; and
``
(B) to identify each such ingredient and, as
applicable, the type of gluten-containing grain.''.

(b) Applicability.--
Section 502 (hh) of the Federal Food, Drug, and Cosmetic Act, as added by subsection (a) , shall apply beginning on the earlier of-- (1) a date to be determined by the Secretary of Health and Human Services; or (2) the date that is 2 years after the date of the enactment of this Act.

(hh) of the Federal Food, Drug, and
Cosmetic Act, as added by subsection

(a) , shall apply beginning on the
earlier of--

(1) a date to be determined by the Secretary of Health and
Human Services; or

(2) the date that is 2 years after the date of the
enactment of this Act.
<all>